Farmakoterapiya gastroezofageal'noy reflyuksnoy bolezni i kachestvo zhizni patsientov


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the pharmacotherapeutic approaches to the treatment of gastroesophageal reflux disease (GERD). The article presents the results of recent randomized clinical trials evaluating the impact of GERD on the quality of life of patients. It is conclude that improving the quality of life is one of the main goals of GERD patients and is considered as an endpoint in evaluating the success of treatment. The development of new dosage forms may contribute to improve the patient’s satisfaction of treatment. Enterosoluble tablet formulation of esomeprazole in the form of preparation Neo-zekst ® is one of these forms.

Full Text

Restricted Access

About the authors

E. A Ushkalova

Email: eushk@yandex.ru

References

  1. Ronkainen J., Agreus L. Epidemiology of reflux symptoms and GORD. Best Pract Res Clin. Gastroenterol. 2013;27(3):325-37.
  2. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России (МЭГРЕ): первые итоги. Экспериментальная и клиническая гастроэнтерология. 2009;6: 4-12.
  3. ElSerag H. Time trends of gastroesophageal reflux disease: a systematic review. Clin. Gastroenterol. Hepatol. 2007. Vol. 5. P. 17-26.
  4. Zagari R.M., Fuccio L., Wallander M.A., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008 Oct;57(10):1354-49.
  5. Dent J., El-Serag H.B., Wallander M.A., Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-17.
  6. Camilleri M., Dubois D., Coulie B., et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin. Gastroenterol Hepatol. 2005;3:543-52.
  7. Sonnenberg A., El-Serag H.B. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999;72:81-92.
  8. Исаков В.А., Морозов С.В., Ставраки Е.С. и др. Анализ распространенности изжоги: национальное эпидемиологическое исследование взрослого городского населения (АРИАДНА). Экспериментальная и клиническая гастроэнтерология. 2008;1:20-9.
  9. Ахунов И.Н. Медико-социальное исследование образа и качества жизни больных гастроэзофагеальной рефлюксной болезнью. Дисс. канд. мед. наук. Казань, 2009.
  10. Rezailashkajani M., Roshandel D., Shafaee S., Zali M.R. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients. Eur. J. Gastroenterol. Hepatol. 2007;19(6):499-506.
  11. Rosaida M.S., Goh K.L. Gastro-oesophageal reflux disease, reflux oesophagitis and non-ero sive reflux disease in a multiracial Asian population: a prospective, endoscopy based study. Eur. J. Gastroenterol. Hepatol. 2004;16(5):495-501.
  12. Koek G.H., Sifrim D., Lerut T., et al. Multivariate analysis of the association of acid and duo-deno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. Gut. 2008;57(8):1056-64.
  13. El-Serag H.B. Epidemiology of non-erosive reflux disease. Digestion. 2008;78(Suppl 1):6-10.
  14. Chen C.L., Hsu P.I. Current advances in the diagnosis and treatment of nonerosive reflux disease. Gastroenterol. Res. Pract. 2013;2013: 653989.
  15. Altomare A., Guarino M.P., Cocca S., et al. Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol. 2013;19(39):6523-28.
  16. Smout A.J.P.M. Endoscopy-negative acid reflux disease. Alimentary Pharmacology and Therapeutics. 1997;11(suppl 2):81-5.
  17. Yi C.-H., Hu C.-T., Chen C.-L. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am. J. Med. Sci. 2007;334(3):168-170.
  18. Kulig M., Leodolter A., Vieth M., et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-76.
  19. Bruley Des Varannes S., Marek L., Humeau B., et al. Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and quality of life of patients. Gastroenterol. Clin. Biol 2006;30:364-70.
  20. Hongo M., Kinoshita Y., Shimozuma K., et al. Psychometric validation of the Japanese translation of the Quality of Life in Reflux and Dyspepsia questionnaire in patients with heartburn. J. Gastroenterol. 2007;42:807-15.
  21. Calleja J.L., Bixquert M., Maldonado J. Impact of nocturnal heartburn on quality of life, sleep, and productivity: the SINERGE study. Dig. Dis. Sci. 2007;52:2858-65.
  22. Farup C., Kleinman L., Sloan S., et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern. Med. 2001; 161:45-52.
  23. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig. Dis 2004;22:108-14.
  24. Venables T.L., Newland R.D., Patel A.C., et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scandinavian J. Gastroenterol. 1997;32(10):965-73.
  25. Tew S., Jamieson G.G., Pilowski I., et al. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis. Esophagus 1997;10:9-15.
  26. Liu X.H., Ke M.Y., Song Z.Q., et al. The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease. Zhonghua Nei Ke Za Zhi. 2005;44(11):818-21.
  27. Tolia V., Essenbacher L., Boyer K., Ager J. Gastroesophageal reflux disease (GERD) questionnaire to assess quality of life (QOL) in patients and parents. J. Pediatr. Gastroenterol. Nutr. 2004;39:S424-25.
  28. Gunasekaran T., Tolia V., Colletti R.B., et al. Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study. BMC Gastroenterol. 2009;9:84.
  29. Quigley E.M., Hungin A.P. Review article: quality-of-life issues in gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 2005;22 (Suppl):41-7.
  30. Revicki D.A., Wood M., Maton P.N., Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am. J. Med. 1998;104:252-58.
  31. Wahlqvist P., Carlsson J., Stalhammar N.O., et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastroesopheal reflux disease (WPAI-GORD) - results from a cross-sectional study. Value Health. 2002;5:106-13.
  32. Talley N.J., Junghard O., Wiklund I.K. Why do patients with gastroesophageal reflux disease have a poor health-related quality of life? Gastroenterology. 2001;120:A423.
  33. Irvine E.J. Quality of life assessment in gastrooesophageal reflux disease. Gut. 2004; 53:iv35-iv39.
  34. Bruley des Varannes S., L fman H.G., et al. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France. BMC Gastroenterol. 2013;13:39.
  35. Jung S.H., Oh J.H., Jie B.S., et al. Typical symptoms rather than extraesophageal symptoms affect the quality of life in gastroesophageal reflux disease. Turk J. Gastroenterol. 2012;23(6):747-52.
  36. Wahlqvist P., Karlsson M., Johnson D., et al. Relationship between symptom load of gastrooesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol. Ther. 2008;27:960-70.
  37. Kahrilas P.J., Jonsson A., Denison H., et al. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. Gut. 2013 Jul 5. [Epub ahead of print]
  38. Tack J., Becher A., Mulligan C., Johnson D.A. The Burden of Disruptive Gastro-oesophageal Reflux Disease on Health-related Quality of Life Aliment Pharmacol Ther. 2012;35(11):1257-66.
  39. Dubois R.W., Aguilar D., Fass R., et al. Consequences of frequent nocturnal GERD among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol. Ther. 2007;25:487-500.
  40. Dean B.B., Aguilar D., Johnson L.F., et al.The relationship between the prevalence of night-time gastroesophageal reflux disease and disease severity. Dig Dis. Sci. 2010;55(4):952-59.
  41. Ishino Y., Sugano K. [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton- pump inhibitors or H2 receptor antagonists]. Nihon Rinsho. 2007;65(5):891-94.
  42. Brook R.A., Wahlqvist P., Kleinman N.L., et al. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol. Ther. 2007;26(6):889-98.
  43. Dean B.B., Crawley J.A., Schmitt C.M., et al. The burden of illness of gastrooesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003;17:1309-17.
  44. Joish V.N., Donaldson G., Stockdale W., et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med. Res. Opin. 2005;21:535-44.
  45. Pace F., Negrini C., Wiklund I., et al. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 2005;22(4):349-56.
  46. Toghanian S., Wahlqvist P., Johnson D.A., et al. The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts. Clin. Drug Investig. 2010;30(3):167-78.
  47. Gisbert J.P., Cooper A., Karagiannis D., et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes. 2009;7:90.
  48. Sigterman K.E., van Pinxteren B., Bonis P.A., et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. 2013;5:CD002095.
  49. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a metaanalysis. Neurogastroenterol Motil. 2012; 24(8):747-57.
  50. Regenbogen E., Helkin A., Georgopoulos R., et al. Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review. Otolaryngol. Head Neck Surg. 2012;146(4):524-32.
  51. Becher A., El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34(6):618-27.
  52. Revicki D.A., Zodet M.W., Joshua-Gotlib S., et al. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes. 2003;1:73.
  53. van Zanten S.J., Henderson C., Hughes N. Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can. J. Gastroenterol. 2012;26(4):196-204.
  54. Dimenas E., Carlsson G., Glise H., Israelsson B., Wiklund I. The relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol. Suppl. 1996;22 8-13.
  55. Kalaitzakis E., Bjornsson E. A review of esome-prazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag. 2007;3(4):653-63.
  56. Kirchheiner J., Glatt S., Fuhr U., et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol. 2009;65(1):19-31.
  57. Kinoshita Y., Adachi K., Fujishiro H. Therapeutic approaches to reflux disease, focusing on acid secretion. J. Gastroenterol. 2003;38(Suppl 15):13-9.
  58. Hunt R. Importance of pH control in the management of GERD. Arch Intern Med 1999;159: 649-57.
  59. Rohss K., Lind T., Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur. J. Clin. Pharmacol. 2004;60(8):531-39.
  60. Miner P.Jr., Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. 2003;98(12):2616-20.
  61. Wilder-Smith C.H., Rohss K., Nilsson-Pieschl C., et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion. 2003;68(4):184-88.
  62. Edwards S.J., Lind T., Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol. Ther. 2006;24(5):743-50.
  63. Edwards S.J., Lind T., Lundell L., DAS R. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol. Ther. 2009;30(6):547-56.
  64. Dominguez-Muooz J.E., Sobrino M. Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease. Drugs. 2005;65(Suppl 1):43-50.
  65. Savarino V., Di Mario F., Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135-53.
  66. Wilder-Smith C., Röhss K., Bokelund Singh S., et al. The effects of dose and timing of esome-prazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. Aliment Pharmacol. Ther. 2010; 32(10):1249-56.
  67. Johnsson F., Hatlebakk J.G., Klintenberg A.C., Rom n J. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J. Gastroenterol. 2003;38(4):347-53.
  68. Vasiliadis K.V., Viazis N., Vlachogiannakos J., et al. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system. Am. J. Gastroenterol. 2010;105(2):308-13.
  69. Kandulski A., Peitz U., Minkemoller K., et al. GERD assessment including pH metry predicts a high response rate to PPI standard therapy. BMC Gastroenterol. 2013;13:12.
  70. Degl' Innocenti A., Guyatt G.H., Wiklund I., et al. The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. Health Qual Life Outcomes. 2005;3:4.
  71. Sahara S., Sugimoto M., Uotani T., et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol. Ther. 2013;38(9):1129-37.
  72. Johnson D.A., Orr W.C., Crawley J.A., et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am. J. Gastroenterol. 2005;100(9):1914-22.
  73. Johnson D., Crawley J.A., Hwang C., Brown K. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances. Aliment Pharmacol. Ther. 2010l;32(2):182-90.
  74. Moayyedi P., Hunt R., Armstrong D., et al. The impact of intensifying acid suppression on sleep disturbance related to gastro-oesophageal reflux disease in primary care. Ther. 2013; 37(7):730-37.
  75. Delchier J., Caekaert A., Barthelemy P., Bensa C. A quality of life (QOL) comparison of 2 strategies for long-term treatment with esomeprazole in mild-moderate erosive oesophagitis (EE). Gut. 2004;53(Suppl. VI): A102, Abs MON-G-150.
  76. Engels L.G.J.B., Klinkenberg Knol E.C., Dekkers C.P.M., et al. Esomeprazole continuous versus on-demand maintenance therapy in 1052 gastro-oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment. Eur. J. Gastroenterol. Hepatol. 2003;15:A50.
  77. Knippig C., Leodolter A., Kulig M., et al. Impact of H. pylori infection on quality of life during treatment with esomeprazole in patients with gastroesophageal reflux disease. Gut. 2002;51(Suppl. III):A211, Abs TUE-G-474.
  78. Wiklund I., Hansen N., Bergheim R., Moum B. Esomeprazole is superior to ranitidine 150 mg bid in maintaining quality of life (QoL) in patients with symptomatic GERD. Scand. J. Gastroenterol. 2003;38(Suppl. 238):22 Abs P2.
  79. Lauritsen K., Junghard O., Eklund S., Wiklund I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux oesophagitis. Gastroenterology. 2002;122(4 Suppl. 1):A200, Abs S1292.
  80. Armstrong D., Veldhuyzen van Zanten S.J.O., Barkun A.N., et al. Cast Study Advisory Board. Quality of life (qol) in uninvestigated dyspepsia (ud) patients following treatment with esomeprazole (e) for 4 and 8 weeks: the confirmatory acid suppression test (cast) study. Can. J. Gastroenterol. 2004;(e-supplement).
  81. Talley N.J., Hawkey C.J., Yeomans N.D., et al. Maintenance of improvement in quality of life dimensions and symptom control following initial treatment of upper GI symptoms with esomeprazole versus placebo in patients on long-term NSAID therapy. Gastroenterology. 2004;126(4 Suppl. 2):A-603, Abs W1276.
  82. Talley N.J., Fullerton S., Junghard O., Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am. J. Gastroenterol. 2001;96:1998-2004 11.
  83. Hansen N., Bergheim R., Fagertun H., et al. Long-term management of patients with symptoms of gastro-oesophageal reflux disease-a Norwegian randomized prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int. J. Clin. Pract. 2006;60:15-22.
  84. El-Dika S., Guyatt G.H., Armstrong D., et al. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol. 2005;5:23-30.
  85. Wiklund I., Talley N.J. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Review of Pharmacoeconomics & Outcomes Research 2003;3:341-50.
  86. Moayyedi P., Armstrong D., Hunt R.H., et al. The gain in quality-adjusted life months by switch ing to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS-a cluster-randomized trial. Am. J. Gastroenterol. 2010;105(11):2341-46.
  87. Aanen M.C., Weusten B.L., Numans M.E., et al. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association. J. Clin. Gastroenterol. 2008;42(5):441-47.
  88. Бельмер С.В., Приворотский В.Ф. Гастроэзофагеальная рефлюксная болезнь у детей: отечественный рабочий протокол 2013 года. Лечащий врач, 2013.N 8. С. 66-71.
  89. Ward R.M., Kearns G.L. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr. Drugs. 2013; 15(2):119-31.
  90. Davidson G., Wenzl T.G., Thomson M., et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr. 2013;163(3):692-8.e1-2.
  91. Pace F., Tonini M., Pallotta S., Molteni P., Porro G.B. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol. Ther. 2007;26(2): 195-204.
  92. Zacny J., Zamakhshary M., Sketris I., Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol. Ther. 2005;21(11):1299-312.
  93. Leodolter A., Penagini R. On-demand therapy is a valid strategy in GERD patients: pros and cons. Dig Dis. 2007;25(3):175-78.
  94. Pace F., Porro G.B. On-demand PPI therapy in GERD. Curr Treat Options Gastroenterol. 2008;11(1):35-42.
  95. Bardhan K.D. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol. 2003;98(3 Suppl):S40-8.
  96. Mummadi R.R., Pasricha P.J. Review: on-demand maintenance therapy with proton pump inhibitors is as effective as continuous therapy for nonerosive GERD. Aliment Pharmacol. Ther. 2005;22(4):349-56.
  97. Talley N.J., Lauritsen K., Tunturi-Hihnala H., et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol. Ther. 2001;(3):347-54.
  98. Talley N.J., Venables T.L., Green J.R., et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur. J. Gastroenterol. Hepatol. 2002;14(8):857-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies